When prostate cancer treatments are mismatched
Ronald Chen, MD of the MGH Cancer Center, together with co-authors Jack Clark, MD of the Boston University School of Public Health, and Judith Manola, MS of the Dana-Farber Cancer Institute recently conducted a study on prostrate cancer. Based on their data, it seems like the quality of life factors may not receive adequate consideration when it comes to matching treatments with patients. This seems to stem from the fact that unlike other types of cancers, prostrate deals with subjects that many patients might be uncomfortable discussing even with a doctor.
As James Talcott, MD says, “Prostate cancer patients experience the same fears and hard decisions as all cancer patients do, but prostate cancer treatment directly affects very personal things that most people aren’t comfortable talking about – urinary, bowel and sexual function.”
To read the news in full, please click here.
Photo credits: Wikipedia



MRI’s have long been used as a diagnostic tool for cancer and the many diseases that plague us. Newer generations of MRI scanners are allowing better scans that tracks treatment success of failure and is now also capable of detecting early signs of the deadly disease that more often goes unnoticed before serious symptoms prompts treatment. Cancer as well all know seldom manifests early signs, abnormalities being known only during later stages of the disease when it has already progressed to a non-treatable stage. Effective use of MRI scans to diagnose, detect and monitor the progression of treatment allowing better views of the deadly disease that is
Men who have high consumption of green tea, long known for its cancer fighting components have shown quite a significant reduction of cancer causing markers according to research. This gives credence to the cancer fighting abilities of Green Tea of which are much hyped phytochemicals. These compounds have long been regarded as
Scientists from the Wayne State University have identified a form of the gene gaectin-3 to be a good indicator of the progression of prostate cancer in patients. Lack of the
Metastatic Prostate Cancer is known to be the main cause of death due to